Skip to main content
  • Medtronic receives FDA approval for its next generation Micra leadless pacing systems

    New pacemakers offer 40% more battery life,1 extend Medtronic legacy of pacing leadership

    DUBLIN, May 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniaturized, leadless pacemakers.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details